tradingkey.logo

Sangamo Therapeutics slides after $25 million stock sale

ReutersFeb 3, 2026 2:27 PM

Shares of genomic medicine firm Sangamo Therapeutics SGMO.O slide 19% to $0.46 premarket

SGMO announces pricing of $25 million stock sale at $0.4719 apiece

Company sold 35.2 million shares and pre-funded warrants to purchase 17.8 million shares in the offering

Proceeds from offering to be used for working capital and general corporate purposes

Cantor and Wells Fargo Securities are joint book-running managers for offering

Three of five brokerages rate the stock "buy" or higher and two "hold"; median PT $2 - data compiled by LSEG

As of last close, SGMO shares down 35.2% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI